Edward A Belongia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1186363/publications.pdf Version: 2024-02-01

	15466	15218
17,511	65	126
citations	h-index	g-index
231	231	14690
docs citations	times ranked	citing authors
	citations 231	17,511 65 citations h-index 231 231

#	Article	IF	CITATIONS
1	mRNA COVIDâ€19 vaccine effectiveness against SARSâ€CoVâ€2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021. Influenza and Other Respiratory Viruses, 2022, 16, 607-612.	1.5	7
2	Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults. Influenza and Other Respiratory Viruses, 2022, 16, 562-567.	1.5	6
3	Vaccine-associated attenuation of subjective severity among outpatients with influenza. Vaccine, 2022, 40, 4322-4327.	1.7	1
4	Factors associated with human papillomavirus and meningococcal vaccination among adolescents living in rural and urban areas. Vaccine: X, 2022, 11, 100180.	0.9	3
5	Human papillomavirus vaccine beliefs and practice characteristics in rural and urban adolescent care providers. BMC Public Health, 2022, 22, .	1.2	5
6	Impact of Immune Priming, Vaccination, and Infection on Influenza A(H3N2) Antibody Landscapes in Children. Journal of Infectious Diseases, 2021, 224, 469-480.	1.9	8
7	Effects of Prior Season Vaccination on Current Season Vaccine Effectiveness in the United States Flu Vaccine Effectiveness Network, 2012–2013 Through 2017–2018. Clinical Infectious Diseases, 2021, 73, 497-505.	2.9	15
8	Influenza Vaccine Effectiveness in Inpatient and Outpatient Settings in the United States, 2015–2018. Clinical Infectious Diseases, 2021, 73, 386-392.	2.9	41
9	Influenza Vaccine Effectiveness: New Insights and Challenges. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038315.	2.9	23
10	Systematic Testing for Influenza and Coronavirus Disease 2019 Among Patients With Respiratory Illness. Clinical Infectious Diseases, 2021, 72, e426-e428.	2.9	4
11	OUP accepted manuscript. American Journal of Epidemiology, 2021, , .	1.6	4
12	Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011–2012 through 2018–2019. Vaccine, 2021, 39, 1788-1796.	1.7	13
13	Risk of symptomatic severe acute respiratory syndrome coronavirus 2 infection not associated with influenza vaccination in the 2019–2020 season. Influenza and Other Respiratory Viruses, 2021, 15, 697-700.	1.5	9
14	Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. Vaccine, 2021, 39, 3614-3620.	1.7	5
15	Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States. Vaccine, 2021, 39, 3324-3328.	1.7	2
16	Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized Open-Label Trial. Clinical Infectious Diseases, 2021, 73, 1973-1981.	2.9	18
17	Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017. Clinical Infectious Diseases, 2021, 72, 1147-1157.	2.9	22
18	Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States—2019–2020. Clinical Infectious Diseases, 2021, 73, e4244-e4250.	2.9	75

#	Article	IF	CITATIONS
19	Clinical Symptoms Among Ambulatory Patients Tested for SARS-CoV-2. Open Forum Infectious Diseases, 2021, 8, ofaa576.	0.4	15
20	Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65–74Âyears. Vaccine, 2021, 39, 7146-7152.	1.7	2
21	Effect of Previous-Season Influenza Vaccination on Serologic Response in Children During 3 Seasons, 2013–2014 Through 2015–2016. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 173-180.	0.6	6
22	Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018–2019 Season. Journal of Infectious Diseases, 2020, 221, 8-15.	1.9	150
23	Effects of Influenza Vaccination in the United States During the 2018–2019 Influenza Season. Clinical Infectious Diseases, 2020, 71, e368-e376.	2.9	72
24	Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014–15. Vaccine, 2020, 38, 2088-2094.	1.7	3
25	Prediction of serious RSVâ€related outcomes in older adults with outpatient RSV respiratory illness during 12 consecutive seasons. Influenza and Other Respiratory Viruses, 2020, 14, 479-482.	1.5	3
26	Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015–16 to 2018–19. Vaccine, 2020, 38, 6562-6569.	1.7	14
27	Patterns of Influenza Vaccination and Vaccine Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness. JAMA Pediatrics, 2020, 174, 705.	3.3	20
28	Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine. Vaccine, 2020, 38, 5880-5884.	1.7	11
29	COVID-19 and flu, a perfect storm. Science, 2020, 368, 1163-1163.	6.0	74
30	Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017–2018. Vaccine, 2020, 38, 3121-3128.	1.7	10
31	Survey of influenza vaccine knowledge, attitudes, and beliefs among pregnant women in the 2016–17 season. Vaccine, 2020, 38, 2202-2208.	1.7	14
32	Serious outcomes of medically attended, laboratoryâ€confirmed influenza illness among schoolâ€aged children with and without asthma, 2007â€2018. Influenza and Other Respiratory Viruses, 2020, 14, 173-181.	1.5	4
33	Interim Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness — United States, February 2020. Morbidity and Mortality Weekly Report, 2020, 69, 177-182.	9.0	102
34	Earliest infections predict the age distribution of seasonal influenza A cases. ELife, 2020, 9, .	2.8	49
35	Interim Estimates of 2018–19 Seasonal Influenza Vaccine Effectiveness — United States, February 2019. Morbidity and Mortality Weekly Report, 2019, 68, 135-139.	9.0	75
36	Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012–13, 2013–14, and 2014–15. Vaccine, 2019, 37, 6673-6681.	1.7	39

#	Article	IF	CITATIONS
37	Incidence of Herpes Zoster Among Children: 2003–2014. Pediatrics, 2019, 144, .	1.0	60
38	Sociodemographic and clinical correlates of human papillomavirus vaccine attitudes and receipt among Wisconsin adolescents. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100168.	4.5	5
39	Influenza Vaccine Effectiveness: Defining the H3N2 Problem. Clinical Infectious Diseases, 2019, 69, 1817-1823.	2.9	81
40	Effects of Influenza Vaccination in the United States During the 2017–2018 Influenza Season. Clinical Infectious Diseases, 2019, 69, 1845-1853.	2.9	218
41	Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics, 2019, 144, .	1.0	30
42	Influenza Vaccine Effectiveness in the United States During the 2016–2017 Season. Clinical Infectious Diseases, 2019, 68, 1798-1806.	2.9	90
43	Hospitalization following outpatient medical care for influenza: <scp>US</scp> influenza vaccine effectiveness network, 2011â€12—2015â€16. Influenza and Other Respiratory Viruses, 2019, 13, 133-137.	1.5	4
44	Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011–2017. Clinical Infectious Diseases, 2019, 68, 1616-1622.	2.9	9
45	Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013–2014 season. Vaccine, 2018, 36, 1214-1219.	1.7	18
46	Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. American Journal of Transplantation, 2018, 18, 756-762.	2.6	24
47	2015–2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States. Clinical Infectious Diseases, 2018, 66, 665-672.	2.9	52
48	Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine, 2018, 36, 1272-1278.	1.7	52
49	Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. Vaccine, 2018, 36, 818-826.	1.7	68
50	An updated influenza A(H3N2) vaccine generates limited antibody responses to previously encountered antigens in children. Vaccine, 2018, 36, 758-764.	1.7	2
51	Interim estimates of 2017–18 seasonal influenza vaccine effectiveness — United States, February 2018. American Journal of Transplantation, 2018, 18, 1020-1025.	2.6	15
52	The Advisory Committee on Immunization Practices recommendation regarding the use of live influenza vaccine: A rejoinder. Vaccine, 2018, 36, 343-344.	1.7	5
53	Pilot screening study of targeted genetic polymorphisms for association with seasonal influenza hospital admission. Journal of Medical Virology, 2018, 90, 436-446.	2.5	10
54	Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons—United States, 2011–2016. Clinical Infectious Diseases, 2018, 66, 1035-1041.	2.9	23

#	Article	IF	CITATIONS
55	Estimated rates of influenzaâ€associated outpatient visits during 2001â€2010 in 6 <scp>US</scp> integrated healthcare delivery organizations. Influenza and Other Respiratory Viruses, 2018, 12, 122-131.	1.5	9
56	Burden of medically attended influenza infection and cases averted by vaccination – United States, 2013/14 through 2015/16 influenza seasons. Vaccine, 2018, 36, 467-472.	1.7	25
57	Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. Morbidity and Mortality Weekly Report, 2018, 67, 103-108.	9.0	420
58	Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012–2016. Vaccine, 2018, 36, 8047-8053.	1.7	16
59	Clinical Features, Severity, and Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults ≥60 Years Old. Open Forum Infectious Diseases, 2018, 5, ofy316.	0.4	64
60	Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine. JAMA Network Open, 2018, 1, e183742.	2.8	32
61	Pneumococcal Conjugate Vaccine Safety in Elderly Adults. Open Forum Infectious Diseases, 2018, 5, ofy100.	0.4	10
62	Influence of Birth Cohort on Effectiveness of 2015–2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. Journal of Infectious Diseases, 2018, 218, 189-196.	1.9	43
63	Determinants of human papillomavirus vaccine attitudes: an interview of Wisconsin parents. BMC Public Health, 2018, 18, 746.	1.2	15
64	Validation of selfâ€reported influenza vaccination in the current and prior season. Influenza and Other Respiratory Viruses, 2018, 12, 808-813.	1.5	73
65	Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA Network Open, 2018, 1, e180243.	2.8	146
66	Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness — United States, February 2018. Morbidity and Mortality Weekly Report, 2018, 67, 180-185.	9.0	146
67	Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. Clinical Infectious Diseases, 2017, 64, ciw816.	2.9	149
68	Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014–2015 season. Vaccine, 2017, 35, 2685-2693.	1.7	30
69	Improving Human Papillomavirus Vaccine Use in an Integrated Health System: Impact of a Provider and Staff Intervention. Journal of Adolescent Health, 2017, 61, 252-258.	1.2	38
70	Prior-Season Vaccination and Risk of Influenza During the 2014–2015 Season in the United States. Journal of Infectious Diseases, 2017, 216, 284-285.	1.9	1
71	Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Review of Vaccines, 2017, 16, 723-736.	2.0	201
72	Live attenuated influenza vaccine use and safety in children and adults with asthma. Annals of Allergy, Asthma and Immunology, 2017, 118, 439-444.	0.5	14

#	Article	IF	CITATIONS
73	Beyond Antigenic Match: Moving Toward Greater Understanding of Influenza Vaccine Effectiveness. Journal of Infectious Diseases, 2017, 216, 1477-1480.	1.9	3
74	Association between parent attitudes and receipt of human papillomavirus vaccine in adolescents. BMC Public Health, 2017, 17, 766.	1.2	33
75	Risk of venous thromboembolism following influenza vaccination in adults aged 50 years and older in the Vaccine Safety Datalink. Vaccine, 2017, 35, 5872-5877.	1.7	15
76	Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12. Vaccine, 2017, 35, 5314-5322.	1.7	79
77	Influenza and Workplace Productivity Loss in Working Adults. Journal of Occupational and Environmental Medicine, 2017, 59, 1135-1139.	0.9	34
78	Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season. New England Journal of Medicine, 2017, 377, 534-543.	13.9	240
79	School absenteeism among schoolâ€aged children with medically attended acute viral respiratory illness during three influenza seasons, 2012â€2013 through 2014â€2015. Influenza and Other Respiratory Viruses, 2017, 11, 220-229.	1.5	27
80	Interim Estimates of 2016–17 Seasonal Influenza Vaccine Effectiveness — United States, February 2017. Morbidity and Mortality Weekly Report, 2017, 66, 167-171.	9.0	90
81	RE: "INVITED COMMENTARY: BEWARE THE TEST-NEGATIVE DESIGN― American Journal of Epidemiology, 2017, 185, 613-613.	1.6	8
82	Influenza Antiviral Use Among High-Risk Outpatients During Four Recent Influenza Seasons—United States, 2011–2015. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
83	Children's Serologic Response to H1N1 Component in Inactivated Influenza Virus (IIV) Vaccine Is Dependent on Prior Season Vaccination Status. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
84	Factors associated with realâ€ŧime RTâ€₽CR cycle threshold values among medically attended influenza episodes. Journal of Medical Virology, 2016, 88, 719-723.	2.5	24
85	Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons. Pharmacoepidemiology and Drug Safety, 2016, 25, 928-934.	0.9	35
86	Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011–2012 and 2012–2013. Pediatric Infectious Disease Journal, 2016, 35, 299-308.	1.1	34
87	Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014–2015. Journal of Infectious Diseases, 2016, 214, 1010-1019.	1.9	101
88	Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infectious Diseases, The, 2016, 16, 942-951.	4.6	518
89	Seasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity With Past and Future Strains. Journal of Infectious Diseases, 2016, 214, 1477-1486.	1.9	15
90	2014–2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clinical Infectious Diseases, 2016, 63, 1564-1573.	2.9	229

#	Article	IF	CITATIONS
91	Effect of Statin Use on Influenza Vaccine Effectiveness. Journal of Infectious Diseases, 2016, 214, 1150-1158.	1.9	37
92	Classification and Regression Tree (CART) analysis to predict influenza in primary care patients. BMC Infectious Diseases, 2016, 16, 503.	1.3	57
93	Respiratory Syncytial Virus in Older Adults. Infectious Diseases in Clinical Practice, 2016, 24, 295-302.	0.1	11
94	Incidence of Medically Attended Respiratory Syncytial Virus and Influenza Illnesses in Children 6–59 Months Old During Four Seasons. Open Forum Infectious Diseases, 2016, 3, ofw081.	0.4	14
95	Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. Pediatrics, 2016, 137, e20153279.	1.0	80
96	Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2–17 years of age in 2013–2014 in the United States. Vaccine, 2016, 34, 77-82.	1.7	63
97	Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013–2014 in the United States. Journal of Infectious Diseases, 2016, 213, 1546-1556.	1.9	159
98	Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults. Journal of Infectious Diseases, 2016, 213, 1115-1123.	1.9	38
99	Deep Sequencing Reveals Potential Antigenic Variants at Low Frequencies in Influenza A Virus-Infected Humans. Journal of Virology, 2016, 90, 3355-3365.	1.5	101
100	Age, serum 25-hydroxyvitamin D and vitamin D receptor (VDR) expression and function in peripheral blood mononuclear cells. Oncotarget, 2016, 7, 35512-35521.	0.8	12
101	Using winter 2009–2010 to assess the accuracy of methods which estimate influenza-related morbidity and mortality. Epidemiology and Infection, 2015, 143, 2399-2407.	1.0	5
102	Validation of Health Event Capture in the Marshfield Epidemiologic Study Area. Clinical Medicine and Research, 2015, 13, 103-111.	0.4	26
103	Use of Influenza Antiviral Medications Among Outpatients at High Risk for Influenza-Associated Complications During the 2013–2014 Influenza Season. Clinical Infectious Diseases, 2015, 60, 1677-1680.	2.9	21
104	Factors associated with maintenance of antibody responses to influenza vaccine in older, community-dwelling adults. BMC Infectious Diseases, 2015, 15, 195.	1.3	18
105	Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial. Open Forum Infectious Diseases, 2015, 2, ofv100.	0.4	16
106	Safety of Measles-Containing Vaccines in 1-Year-Old Children. Pediatrics, 2015, 135, e321-e329.	1.0	38
107	Influenza Vaccine Effectiveness in the United States During 2012-2013: Variable Protection by Age and Virus Type. Journal of Infectious Diseases, 2015, 211, 1529-1540.	1.9	245
108	Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses. Open Forum Infectious Diseases, 2015, 2, ofv052.	0.4	37

#	Article	IF	CITATIONS
109	Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine, 2015, 33, 246-251.	1.7	121
110	Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. Vaccine, 2015, 33, 382-387.	1.7	37
111	Reply: Cochrane rearranged. Vaccine, 2015, 33, 12.	1.7	0
112	The Role of Hemagglutinin in Influenza Virus Transmission. FASEB Journal, 2015, 29, LB62.	0.2	0
113	Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. Morbidity and Mortality Weekly Report, 2015, 64, 10-5.	9.0	144
114	1056Factors Associated with Pre-season Seroprotection to B Lineage Influenza Viruses in Children. Open Forum Infectious Diseases, 2014, 1, S309-S309.	0.4	0
115	1057Factors Associated with Influenza A (H1N1)pdm09 (pH1N1) Vaccine Failure among Children Aged 5-17 Years. Open Forum Infectious Diseases, 2014, 1, S310-S310.	0.4	0
116	1132Seasonal Incidence of Medically Attended RSV and Influenza Illness in Children 6-59 Months Old. Open Forum Infectious Diseases, 2014, 1, S336-S336.	0.4	0
117	Absence of associations between influenza vaccines and increased risks of seizures, Guillain–Barré syndrome, encephalitis, or anaphylaxis in the 2012–2013 season. Pharmacoepidemiology and Drug Safety, 2014, 23, 548-553.	0.9	41
118	Medically Attended Respiratory Syncytial Virus Infections in Adults Aged >=50 Years: Clinical Characteristics and Outcomes. Clinical Infectious Diseases, 2014, 58, 342-349.	2.9	74
119	Reply to Fedson. Journal of Infectious Diseases, 2014, 209, 1301-1302.	1.9	1
120	Influenza Vaccine Effectiveness in the 2011–2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates. Clinical Infectious Diseases, 2014, 58, 319-327.	2.9	303
121	Risk of Intussusception after Monovalent Rotavirus Vaccination. New England Journal of Medicine, 2014, 370, 513-519.	13.9	201
122	Can the rolling cross-sectional survey design be used to estimate the effectiveness of influenza vaccines?. Vaccine, 2014, 32, 6440-6444.	1.7	3
123	Mumps Antibody Response in Young Adults After a Third Dose of Measles-Mumps-Rubella Vaccine. Open Forum Infectious Diseases, 2014, 1, ofu094.	0.4	50
124	Impact of Repeated Vaccination on Vaccine Effectiveness Against Influenza A(H3N2) and B During 8 Seasons. Clinical Infectious Diseases, 2014, 59, 1375-1385.	2.9	234
125	A cross-sectional analysis of symptom severity in adults with influenza and other acute respiratory illness in the outpatient setting. BMC Infectious Diseases, 2014, 14, 231.	1.3	32
126	The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine, 2014, 32, 5390-5398.	1.7	175

#	Article	IF	CITATIONS
127	Influenza vaccination and risk of hospitalization among adults with laboratory confirmed influenza illness. Vaccine, 2014, 32, 453-457.	1.7	29
128	Seasonal Incidence of Medically Attended Respiratory Syncytial Virus Infection in a Community Cohort of Adults ≥50 Years Old. PLoS ONE, 2014, 9, e102586.	1.1	60
129	Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. Morbidity and Mortality Weekly Report, 2014, 63, 137-42.	9.0	53
130	Evaluation of obesity as an independent risk factor for medically attended laboratory onfirmed influenza. Influenza and Other Respiratory Viruses, 2013, 7, 160-167.	1.5	24
131	Vaccination coverage levels among children enrolled in the Vaccine Safety Datalink. Vaccine, 2013, 31, 5822-5826.	1.7	19
132	Influenza Vaccination Is Not Associated With Detection of Noninfluenza Respiratory Viruses in Seasonal Studies of Influenza Vaccine Effectiveness. Clinical Infectious Diseases, 2013, 57, 789-793.	2.9	53
133	A sero-survey of toxoplasmosis in farm and non-farm children from Wisconsin, United States, 1997–1999. BMC Public Health, 2013, 13, 837.	1.2	11
134	Trivalent Inactivated Influenza Vaccine and Spontaneous Abortion. Obstetrics and Gynecology, 2013, 121, 159-165.	1.2	76
135	Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010–2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010–2011 Influenza Season. Journal of Infectious Diseases, 2013, 207, 1262-1269.	1.9	24
136	Inactivated Influenza Vaccines for Prevention of Community-Acquired Pneumonia. Epidemiology, 2013, 24, 530-537.	1.2	19
137	Further Evidence for Bias in Observational Studies of Influenza Vaccine Effectiveness: The 2009 Influenza A(H1N1) Pandemic. American Journal of Epidemiology, 2013, 178, 1327-1336.	1.6	37
138	Effect of Age on the Risk of Fever and Seizures Following Immunization With Measles-Containing Vaccines in Children. JAMA Pediatrics, 2013, 167, 1111.	3.3	65
139	Elementary School-Based Influenza Vaccination: Evaluating Impact on Respiratory Illness Absenteeism and Laboratory-Confirmed Influenza. PLoS ONE, 2013, 8, e72243.	1.1	16
140	Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009–2011. PLoS ONE, 2013, 8, e67185.	1.1	47
141	Effectiveness of Seasonal Influenza Vaccines in the United States During a Season With Circulation of All Three Vaccine Strains. Clinical Infectious Diseases, 2012, 55, 951-959.	2.9	227
142	Risk of Confirmed Guillain-Barre Syndrome Following Receipt of Monovalent Inactivated Influenza A (H1N1) and Seasonal Influenza Vaccines in the Vaccine Safety Datalink Project, 2009-2010. American Journal of Epidemiology, 2012, 175, 1100-1109.	1.6	75
143	Comparison of Nasal and Nasopharyngeal Swabs for Influenza Detection in Adults. Clinical Medicine and Research, 2012, 10, 215-218.	0.4	58
144	Risk of Intussusception Following Administration of a Pentavalent Rotavirus Vaccine in US Infants. JAMA - Journal of the American Medical Association, 2012, 307, 598-604.	3.8	133

#	Article	IF	CITATIONS
145	Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 36-44.	4.6	1,534
146	Clinical and virologic outcomes in patients with oseltamivirâ€resistant seasonal influenza A (H1N1) infections: results from a clinical trial. Influenza and Other Respiratory Viruses, 2012, 6, 153-158.	1.5	8
147	Measles-Containing Vaccines and Febrile Seizures in Children Age 4 to 6 Years. Pediatrics, 2012, 129, 809-814.	1.0	44
148	Quantifying the efficacy of influenza vaccines: Authors' reply. Lancet Infectious Diseases, The, 2012, 12, 660-661.	4.6	1
149	Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004–2005 through 2007–2008. Influenza and Other Respiratory Viruses, 2012, 6, 37-43.	1.5	91
150	Prospective Study of Avian Influenza Infection in Backyard Poultry Flocks and Flock Handlers in Wisconsin. Vector-Borne and Zoonotic Diseases, 2011, 11, 1293-1297.	0.6	11
151	Comparison of influenza vaccine effectiveness using different methods of case detection: Clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Vaccine, 2011, 29, 387-390.	1.7	21
152	Influenza vaccination status is not associated with influenza testing among children: Implications for observational studies of vaccine effectiveness. Vaccine, 2011, 29, 1935-1940.	1.7	13
153	Letter to the Editor. Vaccine, 2011, 29, 4183.	1.7	Ο
154	Influenza vaccine effectiveness in Wisconsin during the 2007–08 season: Comparison of interim and final results. Vaccine, 2011, 29, 6558-6563.	1.7	81
155	Safety of Trivalent Inactivated Influenza Vaccine in Children Aged 24 to 59 Months in the Vaccine Safety Datalink. JAMA Pediatrics, 2011, 165, 749.	3.6	37
156	Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. Communities. PLoS ONE, 2011, 6, e23085.	1.1	103
157	Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink Project. Pediatrics, 2011, 127, S54-S64.	1.0	110
158	The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety. Pediatrics, 2011, 127, S45-S53.	1.0	247
159	Comparing Severity and Outcomes for Seasonal and 2009 H1N1 Infections—Reply. JAMA - Journal of the American Medical Association, 2011, 305, 39.	3.8	Ο
160	Injection Site and Risk of Medically Attended Local Reactions to Acellular Pertussis Vaccine. Pediatrics, 2011, 127, e581-e587.	1.0	24
161	Herpes Zoster and Exposure to the Varicella Zoster Virus in an Era of Varicella Vaccination. American Journal of Public Health, 2010, 100, 1116-1122.	1.5	38
162	Real-Time Surveillance to Assess Risk of Intussusception and Other Adverse Events After Pentavalent, Bovine-Derived Rotavirus Vaccine. Pediatric Infectious Disease Journal, 2010, 29, 1-5.	1.1	185

#	Article	IF	CITATIONS
163	The Looming Rash of Herpes Zoster and the Challenge of Adult Immunization. Annals of Internal Medicine, 2010, 152, 609.	2.0	7
164	Promoting Appropriate Antimicrobial Drug Use in the Outpatient Setting: What Works?. Issues in Infectious Diseases, 2010, , 70-88.	0.1	0
165	Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures. Pediatrics, 2010, 126, e1-e8.	1.0	290
166	Henoch-Schonlein Purpura and Polysaccharide Meningococcal Vaccine. Pediatrics, 2010, 126, e325-e329.	1.0	22
167	Clinical Characteristics and 30-Day Outcomes for Influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) Infections. JAMA - Journal of the American Medical Association, 2010, 304, 1091.	3.8	133
168	Varicella Vaccination and Ischemic Stroke in Children: Is There an Association?. Pediatrics, 2009, 123, e228-e234.	1.0	41
169	Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004–2005 Season to the 2006–2007 Season. Journal of Infectious Diseases, 2009, 199, 159-167.	1.9	288
170	National Institutes of Health consensus development conference statement: Management of hepatitis B. Hepatology, 2009, 49, S4-S12.	3.6	91
171	Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink study. BMC Infectious Diseases, 2009, 9, 165.	1.3	23
172	Patterns of pneumococcal vaccination and revaccination in elderly and non-elderly adults: a Vaccine Safety Datalink study. BMC Infectious Diseases, 2009, 9, 37.	1.3	12
173	Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: A Vaccine Safety Datalink study. Vaccine, 2009, 27, 4912-4916.	1.7	31
174	Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine, 2009, 27, 6546-6549.	1.7	154
175	Risk of immune hemolytic anemia in children following immunization. Vaccine, 2009, 27, 7394-7397.	1.7	10
176	Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans. Science, 2009, 325, 197-201.	6.0	2,127
177	National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B. Annals of Internal Medicine, 2009, 150, 104.	2.0	329
178	Performance of Binax NOW Flu A and B and direct fluorescent assay in comparison with a composite of viral culture or reverse transcription polymerase chain reaction for detection of influenza infection during the 2006 to 2007 season. Diagnostic Microbiology and Infectious Disease, 2008, 62, 162-166.	0.8	40
179	Influenza vaccine for community-acquired pneumonia. Lancet, The, 2008, 372, 352-354.	6.3	13
180	Predictors of Antimicrobialâ€ResistantEscherichia coliin the Feces of Vegetarians and Newly Hospitalized Adults in Minnesota and Wisconsin. Journal of Infectious Diseases, 2008, 197, 430-434.	1.9	28

#	Article	IF	CITATIONS
181	Risk of Immune Thrombocytopenic Purpura After Measles-Mumps-Rubella Immunization in Children. Pediatrics, 2008, 121, e687-e692.	1.0	151
182	Postlicensure Monitoring of Intussusception After RotaTeq Vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics, 2008, 121, 1206-1212.	1.0	106
183	Adamantane-Resistant Influenza Infection During the 2004–05 Season. Emerging Infectious Diseases, 2008, 14, 173-176.	2.0	11
184	Effectiveness of Influenza Vaccination. New England Journal of Medicine, 2007, 357, 2728-2731.	13.9	7
185	Executive Summary-Actions to Strengthen Adult and Adolescent Immunization Coverage in the United States: Policy Principles of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2007, 44, 1529-1531.	2.9	19
186	Performance of Directigen flu A+B enzyme immunoassay and direct fluorescent assay for detection of influenza infection during the 2004–2005 season. Diagnostic Microbiology and Infectious Disease, 2007, 58, 413-418.	0.8	26
187	Antimicrobial Drug–Resistant <i>Escherichia coli</i> from Humans and Poultry Products, Minnesota and Wisconsin, 2002–2004. Emerging Infectious Diseases, 2007, 13, 838-846.	2.0	190
188	Coinfections Acquired from Ixodes Ticks. Clinical Microbiology Reviews, 2006, 19, 708-727.	5.7	294
189	Safety of Trivalent Inactivated Influenza Vaccine in Children 6 to 23 Months Old. JAMA - Journal of the American Medical Association, 2006, 296, 1990.	3.8	121
190	Use of Streptogramin Growth Promoters in Poultry and Isolation of Streptograminâ€ResistantEnterococcus faeciumfrom Humans. Journal of Infectious Diseases, 2006, 194, 1200-1208.	1.9	45
191	Clinician Knowledge and Beliefs after Statewide Program to Promote Appropriate Antimicrobial Drug Use. Emerging Infectious Diseases, 2005, 11, 904-911.	2.0	35
192	Rifampicin Resistance in Tuberculosis Outbreak, London, England. Emerging Infectious Diseases, 2005, 11, 912-920.	2.0	83
193	Demand for Prophylaxis after Bioterrorism-Related Anthrax Cases, 2001. Emerging Infectious Diseases, 2005, 11, 42-47.	2.0	18
194	Validation of a Screening Instrument to Identify Persons for Exclusion from Smallpox Vaccination. Clinical Infectious Diseases, 2005, 40, 620-623.	2.9	5
195	Spectrum Bias of a Rapid Antigen Detection Test for Group A Â-Hemolytic Streptococcal Pharyngitis in a Pediatric Population. Pediatrics, 2004, 114, 182-186.	1.0	223
196	Appropriateness of Lyme Disease Serologic Testing. Annals of Family Medicine, 2004, 2, 341-344.	0.9	23
197	Smallpox Vaccine: The Good, the Bad, and the Ugly. Clinical Medicine and Research, 2003, 1, 87-92.	0.4	130
198	Diarrhea Incidence and Farmâ€Related Risk Factors forEscherichia coliO157:H7 andCampylobacter jejuniAntibodies among Rural Children. Journal of Infectious Diseases, 2003, 187, 1460-1468.	1.9	60

#	Article	IF	CITATIONS
199	Importance of Primer Specificity for PCR Detection of Anaplasma phagocytophila among Ixodes scapularis Ticks from Wisconsin. Journal of Clinical Microbiology, 2003, 41, 4006-4006.	1.8	9
200	Eczematous Skin Disease and Recall of Past Diagnoses: Implications for Smallpox Vaccination. Annals of Internal Medicine, 2003, 139, 1.	2.0	53
201	Septic system density and infectious diarrhea in a defined population of children Environmental Health Perspectives, 2003, 111, 742-748.	2.8	92
202	Lyme Disease Incidence in Wisconsin: A Comparison of State-reported Rates and Rates from a Population-based Cohort. American Journal of Epidemiology, 2002, 155, 1120-1127.	1.6	41
203	Antibiotic Use and Upper Respiratory Infections: A Survey of Knowledge, Attitudes, and Experience in Wisconsin and Minnesota. Preventive Medicine, 2002, 34, 346-352.	1.6	125
204	Epidemiology and Impact of Coinfections Acquired fromIxodesTicks. Vector-Borne and Zoonotic Diseases, 2002, 2, 265-273.	0.6	115
205	Outcomes of Treated Human Granulocytic Ehrlichiosis Cases. Emerging Infectious Diseases, 2002, 8, 398-401.	2.0	35
206	A randomized trial of zinc nasal spray for the treatment of upper respiratory illness in adults. American Journal of Medicine, 2001, 111, 103-108.	0.6	47
207	Congenital Syphilis Surveillance and Newborn Evaluation in a Low-Incidence State. JAMA Pediatrics, 2001, 155, 140.	3.6	18
208	A Community Intervention Trial to Promote Judicious Antibiotic Use and Reduce Penicillin-Resistant Streptococcus pneumoniae Carriage in Children. Pediatrics, 2001, 108, 575-583.	1.0	126
209	Tickborne Infections as a Cause of Nonspecific Febrile Illness in Wisconsin. Clinical Infectious Diseases, 2001, 32, 1434-1439.	2.9	42
210	<i>Ixodes scapularis</i> (Acari: Ixodidae): Abundance and Rate of Infection with <i>Borrelia burgdorferi</i> in Four State Parks in Wisconsin. Journal of Medical Entomology, 2001, 38, 33-38.	0.9	17
211	Clinical and Epidemiological Features of Early Lyme Disease and Human Granulocytic Ehrlichiosis in Wisconsin. Clinical Infectious Diseases, 1999, 29, 1472-1477.	2.9	94
212	Physicians' Practices and Opinions Regarding Prenatal Screening for Human Immunodeficiency Virus and Other Sexually Transmitted Diseases. Sexually Transmitted Diseases, 1998, 25, 169-175.	0.8	17
213	A Population-Based Study of Sexually Transmitted Disease Incidence and Risk Factors in Human Immunodeficiency Virus-Infected People. Sexually Transmitted Diseases, 1997, 24, 251-256.	0.8	30
214	Factors Associated With the Geographic Variation of Reported Chlamydia Infection in Minnesota. Sexually Transmitted Diseases, 1994, 21, 70-75.	0.8	4
215	Transmission of Escherichia coli 0157:H7 Infection in Minnesota Child Day-care Facilities. JAMA - Journal of the American Medical Association, 1993, 269, 883.	3.8	109
216	Ocular Involvement in an Outbreak of Herpes Gladiatorum. American Journal of Ophthalmology, 1992, 114, 680-684.	1.7	42

#	Article	IF	CITATIONS
217	Herpes Gladiatorum. New England Journal of Medicine, 1992, 326, 647-648.	13.9	3
218	3-(Phenylamino)alanine, a Novel Aniline-Derived Amino Acid Associated With the Eosinophilia-Myalgia Syndrome: A Link to the Toxic Oil Syndrome?. Mayo Clinic Proceedings, 1992, 67, 1134-1139.	1.4	65
219	An Outbreak of Escherichia coli 0157:H7 Colitis Associated with Consumption of Precooked Meat Patties. Journal of Infectious Diseases, 1991, 164, 338-343.	1.9	119
220	Methicillinâ€Resistant <i>Staphylococcus aureus</i> in Minnesota Nursing Homes. Journal of the American Geriatrics Society, 1991, 39, 1105-1109.	1.3	20
221	An Outbreak of Herpes Gladiatorum at a High-School Wrestling Camp. New England Journal of Medicine, 1991, 325, 906-910.	13.9	142
222	An Investigation of the Cause of the Eosinophilia–Myalgia Syndrome Associated with Tryptophan Use. New England Journal of Medicine, 1990, 323, 357-365.	13.9	363
223	Premarital HIV Screening-Reply. JAMA - Journal of the American Medical Association, 1989, 261, 2198.	3.8	1
224	Border Hopping as a Consequence of Premarital HIV Screening: The Kenosha Diamond. JAMA - Journal of the American Medical Association, 1988, 260, 1883.	3.8	11
225	The Trauma Score as a Triage Tool. JAMA - Journal of the American Medical Association, 1987, 257, 484.	3.8	1